Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board

Abstract:
Heritage in Genomic Profiling and Molecular Medicine Tightly Linked with VisEn's Molecular Imaging Technology Platforms and Development Programs

VisEn Medical, Inc., a leader in fluorescence in vivo imaging of biologic and molecular activities from research through medicine, today announced that Geoffrey S. Ginsburg, M.D., Ph.D. has joined its Scientific Advisory Board.

Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board

Woburn, MA | Posted on December 8th, 2006

Dr. Ginsburg is Professor of Medicine and Pathology and Director of the Center for Genomic Medicine at Duke University's Institute for Genome Sciences & Policy. Dr. Ginsburg's work centers on the identification and application of predictive biomarkers in developing and applying novel therapies and for improved research and clinical medicine.

VisEn's fluorescence imaging technologies provide the industry's most robust imaging performance in identifying, characterizing and quantifying a range of biomarkers in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research, more efficient drug development, and truly tailored clinical medicine into the future.

Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement, "Dr. Ginsburg's deep heritage and expertise in genomics, biomarkers, pharmaceutical development and personalized medicine builds directly into VisEn's mission of developing and applying fluorescence imaging technologies from in vivo research through clinical medicine. We are honored by his participation with VisEn and see this as yet another key foundation for our company's leadership in clinically directed molecular imaging."

Dr. Ginsburg stated, "The future of clinical medicine will be built around linked understandings, readouts and treatments of disease-related biomarkers in patient populations. VisEn's real-time in vivo imaging of biologic and molecular processes is playing an increasingly central role in basic research and drug development today, and there is a close parallel between these approaches and the advanced molecular profiling work being carried out at our center."

"By bringing together the industry experts and leaders in the fields of genomics, biomarkers, imaging and therapeutic intervention, we will work to produce new approaches to pharmaceutical development and personalized medicine that will have a truly positive impact on healthcare delivery," added Dr. Ginsburg. "I look forward to collaborating even more deeply with VisEn's
leading Scientific Advisory Board to further advance this promising new area of medicine."

Prior to his academic career, Dr. Ginsburg was Director of Cardiovascular Disease and Vice President of Molecular and Personalized Medicine at Millennium Pharmaceuticals. In these roles, he was responsible for Millennium's personalized medicine initiatives to develop biomarkers for disease
and pharmacogenomic strategies for therapeutics and their implementation in the drug development process. His responsibilities also included translational research efforts and strategic academic alliances required to integrate genomics into the practice of medicine.

####

About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and
Harvard Medical School. VisEn is developing today's highest performing
fluorescence molecular imaging technology platforms, from research through
medicine. VisEn also works directly with its partners to design ranges of
tailored probes and applications that are targeted to their specific research
areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and
has been financed by leading venture firms including Flagship Ventures and
The Bollard Group. For further information please visit http://www.visenmedical.com.

For more information, please click here

Contacts:
Bryan Murphy
LaVoie Group
978.745.4200 x105

Copyright © VisEn Medical, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Chemical cages: New technique advances synthetic biology February 10th, 2016

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Superconductivity: Footballs with no resistance - Indications of light-induced lossless electricity transmission in fullerenes contribute to the search for superconducting materials for practical applications February 9th, 2016

SUNY Poly and GLOBALFOUNDRIES Announce New $500M R&D Program in Albany To Accelerate Next Generation Chip Technology: Arrival of Second Cutting Edge EUV Lithography Tool Launches New Patterning Center That Will Generate Over 100 New High Tech Jobs at SUNY Poly February 9th, 2016

Tools

Making sense of metallic glass February 9th, 2016

Chiral magnetic effect generates quantum current: Separating left- and right-handed particles in a semi-metallic material produces anomalously high conductivity February 8th, 2016

Metal oxide sandwiches: New option to manipulate properties of interfaces February 8th, 2016

Researchers discover new phase of boron nitride and a new way to create pure c-BN February 5th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Tesla NanoCoatings Gains Talents of Joe Davis as Vice President-Sales Engineer January 27th, 2016

Semblant Appoints Donald Cunningham as Chief Commercial Officer January 2nd, 2016

Beneq introduces new growth strategy and company structure - Jukka Nieminen appointed President December 15th, 2015

Kerstin Kleese van Dam Named Director of Brookhaven Lab's Computational Science Initiative September 26th, 2015

Human Interest/Art

Rice to enter first international nanocar race: Five teams will participate in October 2016 event in France December 15th, 2015

Bionic liver micro-organs explain off-target toxicity of acetaminophen (Tylenol): Israeli-German partnership aims to replace animal experiments with advanced liver-on-chip devices August 17th, 2015

Omni Nano and Time Warner Cable Partner to Provide Nanotechnology Education to the Boys & Girls Clubs of Los Angeles: A $10,000 Donation to Benefit Youth of Los Angeles County's Boys & Girls Clubs August 4th, 2015

Kalam: versatility personified August 1st, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic